CHADS₂ Score for Atrial Fibrillation Stroke Risk

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
chads2 assessment
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–0
  • Low-Intermediate Risk1–1
  • Intermediate Risk2–2
  • High Risk3–3
Direct Clinical Answer

The CHADS₂ Score for Atrial Fibrillation Stroke Risk calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include congestive heart failure. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Clinical prediction tool that estimates annual stroke risk in patients with atrial fibrillation. Helps determine whether anticoagulation therapy is warranted based on patient's risk profile for thromboembolic events. Developed from the National Registry of Atrial Fibrillation and validated in multiple populations.

Clinical Indication

The CHADS₂ Score for Atrial Fibrillation Stroke Risk is indicated for bedside clinical practice to support Clinical prediction tool that estimates annual stroke risk in patients with atrial fibrillation. Helps determine whether anticoagulation therapy is warranted based on patient's risk profile for thromboembolic events. Developed from the National Registry of Atrial Fibrillation and validated in multiple populations.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.

Limitations & Contraindications

In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.

Clinical Pearls & Action Plan

Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines. Guideline pearl: Score 2: 4.0% annual stroke risk - generally recommend anticoagulation.

Formula & Variables:

CHADS₂ Score = Congestive heart failure (1) + Hypertension (1) + Age ≥75 years (1) + Diabetes mellitus (1) + Stroke/TIA/thromboembolism history (2). Total range: 0-6 points.

Input Parameters

NameTypeRequiredDescription
congestive_heart_failurestringYesHistory of congestive heart failure or left ventricular dysfunction
hypertensionstringYesHistory of hypertension or current antihypertensive treatment
age_75_or_olderstringYesPatient age 75 years or older
diabetes_mellitusstringYesHistory of diabetes mellitus or current antidiabetic treatment
stroke_tia_thromboembolismstringYesPrevious stroke, transient ischemic attack, or thromboembolism

Score Interpretation & Guidance

RangeStageDescription
0–0Low RiskLow annual stroke risk
1–1Low-Intermediate RiskLow-intermediate annual stroke risk
2–2Intermediate RiskIntermediate annual stroke risk
3–3High RiskHigh annual stroke risk
4–4High RiskHigh annual stroke risk
5–5Very High RiskVery high annual stroke risk
6–6Very High RiskVery high annual stroke risk

Evidence-Based References (EBM)

  • Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-70.
  • Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287-92.
  • Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
  • Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):546S-592S.

Related calculators